January 8, 2026/
On January 5, 2026, the landscape of weight management in America shifted with the broad availability of Novo Nordisk's Wegovy® (semaglutide) pill. As the first and only...
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
On January 5, 2026, the landscape of weight management in America shifted with the broad availability of Novo Nordisk's Wegovy® (semaglutide) pill. As the first and only...
A new international study protocol, published by the World Health Organization (WHO) in 2025, lays the groundwork for a critical public health initiative: determining how often...
In a significant regulatory decision, the U.S. Food and Drug Administration (FDA) has approved an update to the label for the long-acting contraceptive Depo-Provera (medroxyprogesterone acetate). The...
